Skip to main content

Table 2 Rating scale assessments

From: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

Rating scale

 

UPDRS Part I (mentation, behavior and mood); mean ± SD

 Baseline (n = 477)

2.3 ± 2.1

 3 months (n = 393)

1.9 ± 1.9

 Change from baseline (n = 393)

− 0.3 ± 1.5

UPDRS Part II (ADL during OFF); mean ± SD

 Baseline (n = 476)

17.1 ± 7.0

 3 months (n = 391)

13.9 ± 6.8

 Change from baseline (n = 391)

− 3.0 ± 4.6

P value vs. baseline

< 0.0001

UPDRS Part III (motor scores during ON); mean ± SD

 Baseline (n = 477)

26.5 ± 12.1

 3 months (n = 393)

21.5 ± 11.0

 Change from baseline (n = 393)

− 4.6 ± 8.1

P value vs. baseline

< 0.0001

UPDRS Total scores (Part II + III); mean ± SD

 Baseline (n = 477)

37.5 ± 16.9

 3 months (n = 393)

30.5 ± 15.2

 Change from baseline (n = 393)

− 6.4 ± 10.4

P value vs. baseline

< 0.0001

UPDRS Part IV (complications of therapy); mean ± SD

 Baseline (n = 475)

5.2 ± 2.6

 3 months (n = 391)

4.2 ± 2.4

 Change from baseline (n = 391)

− 0.8 ± 1.9

PDQ-8 Total Score; mean ± SD

 Baseline (n = 476)

29.2 ± 16.4

 3 months (n = 393)

25.2 ± 15.8

 Change from baseline (n = 393)

− 3.4 ± 12.8

P value vs. baseline

< 0.0001

NMSS Score; mean ± SD

 Baseline (n = 477)

44.6 ± 30.3

 3 months (n = 393)

37.0 ± 26.7

 Change from baseline (n = 393)

− 6.8 ± 19.7

P value vs. baseline

< 0.0001

  1. NMSS Non-motor symptom scale, UPDRS Unified Parkinson’s Disease Rating Scale, PDQ-8 Parkinson’s Disease Questionnaire